Previous 10 | Next 10 |
Exelixis (NASDAQ: EXEL) , founded in 1994, is a commercial stage biotech company with U.S. Food and Drug Administration-approved drugs to treat advanced cases of thyroid, kidney, and liver cancer. Its lead drug goes by the medical name of cabozantinib, but uses the marketing brand n...
Exelixis (EXEL) up 3% on announcing results from Phase 3 trial, COSMIC-311, evaluating cabozantinib (Cabometyx) in radioiodine-refractory differentiated thyroid cancer patients who have progressed after up to two prior vascular endothelial growth factor receptor targeted ...
– Cabozantinib reduced the risk of disease progression or death by 78%; hazard ratio = 0.22, (p<0.0001) compared to placebo – – Exelixis will discuss the trial results and regulatory filing plans with the U.S. Food and Drug Adminis...
REDWOOD CITY, Calif. and WUHAN, China, Dec. 16, 2020 (GLOBE NEWSWIRE) -- XWPharma Ltd. today announced that Michael M. Morrissey, Ph.D. has been appointed to the company’s Board of Directors. Dr. Morrissey brings extensive experience as a scientist, leader of high...
Exelixis ([[EXEL]] +1.6%) exercises its option for Aurigene's CDK7 inhibitor, now known as XL102, and submits an Investigational New Drug Application to the U.S. Food and Drug Administration to evaluate XL102 alone or in combination therapy for treatment of inoperable locally advanced or meta...
– Phase 1 clinical trial expected to begin in Q1 2021 – – Under the terms of the companies’ agreement, Exelixis will make an option exercise payment of $12 million to Aurigene – – Promising preclinical data support fu...
Exelixis ([[EXEL]] -1.3%) has exercised its exclusive option for Iconic Therapeutic’s lead oncology antibody-drug conjugate ((ADC)) program under the companies’ May 2019 agreement.Now Exelixis will be responsible for clinical development, commercialization, and manufac...
– Phase 1 clinical trial planned for early 2021, pending the FDA’s acceptance of Exelixis’ planned IND filing – – Under the terms of the companies’ agreement, Exelixis has made an option exercise payment of $20 million to...
Exelixis, Inc. (EXEL) Evercore ISI 3rd Annual HealthCONx Conference December 1, 2020 3:05 PM ET Company Participants Michael Morrissey - President and Chief Executive Officer Conference Call Participants Josh Schimmer - Evercore ISI Presentation Josh Schimmer Welcome everyone. This is Josh Sc...
Exelixis' (EXEL) partner Takeda Pharmaceutical (TAK) has received Japanese approval to manufacture and market Cabometyx as a treatment for patients with unresectable hepatocellular carcinoma ((HCC)) that has progressed after prior systemic therapy. Per the terms of Exelixis and Take...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...